SCHEMBL2144152

SCHEMBL2144152

CC(C)(C)OC(=O)Nc1cccc(CC(=O)C2CCN(C(=O)O)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STS P08842 2/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
KMT2A Q03164 3/20 0.37
TGFBR1 P36897 1/20 0.37
MAPK1 P28482 1/20 0.37
PTPRB P23467 1/20 0.37
PTPN11 Q06124 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36
HSD11B1 P28845 1/20 0.36
GLS O94925 1/20 0.36
PARP1 P09874 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2144382 0.92 PTPN2 (0.48) STSPTPN2PTPN1PTPN6KMT2A
SCHEMBL27822346 0.87 TGFBR1 (0.37) PTPN2PTPN1PTPN6TGFBR1HSD11B1
SCHEMBL2144850 0.84 KDM4E (0.41) TGFBR1KDM4EPKMPARP1
SCHEMBL2145399 0.82 GPR119 (0.38) STSKMT2ATGFBR1MAPK1KDM4E
Tert-Butyl Formate SCHEMBL27822347 0.79 CCR2 (0.37) TGFBR1GLS
SCHEMBL3427899 0.79 PDE5A (0.50) KMT2ANPC1RAB9AKDM4EGLS
SCHEMBL2144272 0.78 MMP13 (0.36) STSKMT2ATGFBR1
SCHEMBL4731287 0.76 GRIN2B (0.37) TGFBR1KDM4EPKMGLS
SCHEMBL2144952 0.76 KDM4E (0.48) STSPTPN2PTPN1PTPN6TGFBR1
SCHEMBL2144363 0.76 PARP1 (0.35) STSPTPN2PTPN1PTPN6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344494-B1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARM LLC (US) 2016-04-20 EP disclosed
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BAHMANYAR SOGOLE (US) 2013-01-03 US disclosed
US-8299056-B2 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2012-10-30 US disclosed
EP-2344494-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS Signal Pharmaceuticals, LLC (US) 2011-07-20 EP disclosed
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 US disclosed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 STS 3152/4885PTPN2 845/4885PTPN1 1078/4885
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 STS 3152/4885PTPN2 845/4885PTPN1 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.